• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $AKRO

    Akero Therapeutics Inc.

    Subscribe to $AKRO
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

    IPO Year: 2019

    Exchange: NASDAQ

    Website: akerotx.com

    Peers

    $CTMX
    $MDGL

    Recent Analyst Ratings for Akero Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    1/30/2025$35.00 → $63.00Neutral → Buy
    BofA Securities
    1/27/2025$50.00 → $72.00Buy
    H.C. Wainwright
    11/18/2024$65.00Buy
    Citigroup
    4/22/2024$30.00Neutral
    BofA Securities
    9/19/2023$69.00Overweight
    Cantor Fitzgerald
    8/28/2023$83.00Buy
    UBS
    1/27/2023$40.00 → $65.00Equal-Weight → Overweight
    Morgan Stanley
    9/14/2022$10.00 → $50.00In-line → Outperform
    Evercore ISI
    11/15/2021$27.00 → $29.00Equal-Weight
    Morgan Stanley
    11/15/2021$64.00 → $62.00Buy
    HC Wainwright & Co.
    See more ratings

    Akero Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine

      Results support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in patients with compensated cirrhosis (F4 fibrosis) due to MASH 96-week data from SYMMETRY trial presented at EASL Congress 2025 SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced publication of results from the Phase 2b SYMMETRY trial in the New England Journal of Medicine. The publication reports results from the 96-week SYMMETRY study evaluating the efficacy and safety of Akero's lead FGF21

      5/9/25 7:11:31 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025

      SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, presented results from the Phase 2b SYMMETRY trial demonstrating the potential of efruxifermin (EFX) to improve fibrosis in compensated cirrhosis (F4) caused by metabolic dysfunction-associated steatohepatitis (MASH), in a late-breaking oral presentation at the European Association for the Study of the Liver (EASL) Congress 2025 taking place May 7-10, in Amsterdam, the Netherlands. "Compensated cirrhosis due to MASH remains a high unmet medical ne

      5/9/25 6:15:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference

      SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 1:40 p.m. P.T. A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website. About Akero TherapeuticsAkero Therapeutics is a clinical-stage company dev

      5/7/25 4:05:00 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025

      SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two oral presentations and an upcoming poster presentation at the European Association for the Study of the Liver (EASL) Congress 2025 taking place May 7-10, 2025, in Amsterdam, the Netherlands. Details for the presentations are as follows: Oral presentation 1 Title: Efruxifermin improves fibrosis in participants with compensated cirrhosis due to MASH: results of a 96-week, randomized, double-blind, placebo-controlled, phase 2b

      4/30/25 7:00:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      -- Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX) in Phase 2b SYMMETRY study -- -- Completed enrollment of the double-blinded portion of the Phase 3 SYNCHRONY Real-World Study evaluating EFX in patients with either MASLD or MASH -- -- Presented New Analyses of Week 96 Phase 2b HARMONY in Patients with Pre-Cirrhotic (F2-F3) MASH at the 75th Annual AASLD The Liver Meeting® 2024 -- SOUTH SAN FRANCISCO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic dise

      2/28/25 7:00:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

      SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the closing of its previously announced underwritten public offering of (i) 6,427,170 shares of its common stock at a public offering price of $48.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,093,750 shares of common stock, and (ii) in lieu of common stock to certain investors, pre-funded warrants to purchase 1,958,247 shares of common stock at a public offer

      1/30/25 4:05:00 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

      SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the pricing of an upsized underwritten public offering of 5,333,420 shares of its common stock at a public offering price of $48.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 1,958,247 shares of common stock at a public offering price of $47.9999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share

      1/28/25 9:30:00 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics Announces Proposed Public Offering of Common Stock

      SOUTH SAN FRANCISCO, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today that it has commenced an underwritten public offering of $300.0 million of shares of its common stock. All of the shares in the proposed offering are being offered by Akero. In addition, Akero intends to grant the underwriters a 30-day option to purchase up to an additional $45.0 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market

      1/27/25 4:01:00 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

      Among patients with baseline and week 96 biopsies, 39% of the 50mg EFX group (p=0.009) demonstrated ≥1 stage improvement in fibrosis with no worsening of MASH, representing a 24% effect size over placebo at 15% By ITT analysis, with all missing week 96 biopsies treated as failures, 29% of the 50mg EFX group (p=0.031) demonstrated ≥1 stage improvement in fibrosis with no worsening of MASH, representing a 17% effect size over placebo at 12% Investor webcast at 8:00 am ET Monday, January 27, 2025 SOUTH SAN FRANCISCO, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious me

      1/27/25 6:30:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

      Investor webcast on Monday, January 27, 2025, at 8:00 a.m. ET to present clinical data SOUTH SAN FRANCISCO, Calif., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, will hold an investor conference on Monday, January 27, 2025, at 8:00 a.m. ET to share preliminary topline week 96 results from its SYMMETRY study, a double-blind, placebo-controlled Phase 2b study evaluating the efficacy of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to metabolic dysfunction-associated steatohepatitis (MASH). Conferenc

      1/24/25 4:05:00 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Akero Therapeutics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Graham G. Walmsley bought $8,787,921 worth of shares (200,000 units at $43.94) (SEC Form 4)

      4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

      3/27/25 7:42:13 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Graham G. Walmsley bought $9,600,000 worth of shares (200,000 units at $48.00) (SEC Form 4)

      4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

      2/7/25 7:54:28 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Graham G. Walmsley bought $1,982,940 worth of shares (100,000 units at $19.83) (SEC Form 4)

      4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

      12/11/23 9:06:30 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Graham G. Walmsley bought $1,694,565 worth of shares (100,000 units at $16.95) (SEC Form 4)

      4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

      12/5/23 8:37:03 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Akero Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Akero Therapeutics Inc.

      SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

      11/14/24 3:59:41 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Akero Therapeutics Inc.

      SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

      11/14/24 1:22:38 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Akero Therapeutics Inc.

      SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

      11/14/24 6:51:23 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Akero Therapeutics Inc.

      SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

      11/13/24 9:45:23 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Akero Therapeutics Inc.

      SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

      11/8/24 10:52:39 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Akero Therapeutics Inc.

      SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

      10/17/24 11:13:37 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Akero Therapeutics Inc.

      SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

      9/9/24 9:09:39 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Akero Therapeutics Inc. (Amendment)

      SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

      6/10/24 4:17:02 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Akero Therapeutics Inc.

      SC 13G - Akero Therapeutics, Inc. (0001744659) (Subject)

      3/15/24 10:08:36 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Akero Therapeutics Inc. (Amendment)

      SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

      2/14/24 4:26:22 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Akero Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

      -- Initiated Phase 3 SYNCHRONY Outcomes Trial of Lead Candidate Efruxifermin (EFX) in Patients with Compensated Cirrhosis (F4) Due to MASH -- Presented Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024 -- -- Leadership Team Expanded with Addition of Scott Gangloff as Chief Technical Officer -- SOUTH SAN FRANCISCO, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported second quarter financial results for the period ending June 30, 2024 and provided business updates. "The second

      8/9/24 7:00:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

      SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease, today announced the appointment of Scott Gangloff as Chief Technology Officer. "I am delighted to welcome Scott to Akero. His depth of experience leading drug manufacturing for both national and multi-national biopharmaceutical organizations enriches our company with an invaluable perspective during the late-stage clinical development of efruxifermin," remarked Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. "The entire leadership team looks forward to

      4/30/24 8:00:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy

      SOUTH SAN FRANCISCO, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced the appointment of Patrick Lamy as Senior Vice President, Commercial Strategy. "Akero is thrilled to welcome Patrick to the team, especially following last year's HARMONY study results, which further demonstrate EFX's potential to treat NASH holistically and reverse fibrosis rapidly," said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. "Patrick's extensive experience in liver disease, and commercial stra

      1/10/23 8:00:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fate Therapeutics Appoints Yuan Xu to its Board of Directors

      SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced the appointment of Yuan Xu, Ph.D., to its Board of Directors as an independent director. Dr. Xu brings to Fate Therapeutics over 25 years of discovery, development, manufacturing, and commercial experience in the global biopharmaceuticals business, most recently serving as the Chief Executive Officer and Board Member of Legend Biotech Corporation where she led the company's efforts in advancing ciltacabtagene autoleucel (cilta-cel) from proof-of-concept in 2018 to BLA pr

      8/4/21 8:00:00 AM ET
      $AKRO
      $FATE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Akero Therapeutics Appoints Judy Chou, Ph.D., to its Board of Directors

      SOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced the appointment of Judy Chou, Ph.D., to its board of directors as an independent director. "Dr. Chou's expertise in biomanufacturing and protein therapeutic development and experience managing regulatory filings and commercial launches make her an asset to our Board," said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero Therapeutics. "Akero is fortunate to welcome Dr. Chou and benefit from her strategic insights, particularly

      7/14/21 8:00:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics Appoints Yuan Xu to its Board of Directors

      SOUTH SAN FRANCISCO, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced the appointment of Yuan Xu, Ph.D., to its board of directors as an independent director. "Dr. Xu's extensive experience in establishing and leading biopharmaceutical development and manufacturing capabilities brings a complementary perspective to our Board," said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero Therapeutics. "The Akero leadership team looks forward to working with Dr. Xu as we enter late-stage development of o

      4/26/21 8:00:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Akero Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Rolph Timothy exercised 12,500 shares at a strike of $21.10 and sold $542,864 worth of shares (12,500 units at $43.43) (SEC Form 4)

      4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

      5/8/25 7:34:34 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Rolph Timothy exercised 6,250 shares at a strike of $21.10 and sold $256,438 worth of shares (6,250 units at $41.03) (SEC Form 4)

      4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

      4/28/25 6:22:04 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Development Officer Yale Catriona exercised 9,073 shares at a strike of $21.10 and sold $343,962 worth of shares (9,073 units at $37.91) (SEC Form 4)

      4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

      4/16/25 6:00:05 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Cheng Andrew sold $1,056,780 worth of shares (30,000 units at $35.23), decreasing direct ownership by 5% to 624,324 units (SEC Form 4)

      4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

      4/11/25 6:00:05 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Rolph Timothy sold $224,262 worth of shares (6,250 units at $35.88) and exercised 6,250 shares at a strike of $21.10 (SEC Form 4)

      4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

      4/10/25 6:00:04 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Graham G. Walmsley bought $8,787,921 worth of shares (200,000 units at $43.94) (SEC Form 4)

      4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

      3/27/25 7:42:13 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Development Officer Yale Catriona exercised 10,000 shares at a strike of $21.10 and sold $447,605 worth of shares (10,000 units at $44.76) (SEC Form 4)

      4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

      3/18/25 5:30:17 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Cheng Andrew sold $78,001 worth of shares (1,738 units at $44.88), decreasing direct ownership by 0.26% to 654,324 units (SEC Form 4)

      4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

      3/14/25 9:18:12 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Young Jonathan sold $27,242 worth of shares (607 units at $44.88), decreasing direct ownership by 0.30% to 200,540 units (SEC Form 4)

      4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

      3/14/25 8:33:23 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Development Officer Yale Catriona sold $27,556 worth of shares (614 units at $44.88), decreasing direct ownership by 0.64% to 95,034 units (SEC Form 4)

      4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

      3/14/25 8:30:03 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Akero Therapeutics Inc. SEC Filings

    See more
    • SEC Form DEF 14A filed by Akero Therapeutics Inc.

      DEF 14A - Akero Therapeutics, Inc. (0001744659) (Filer)

      4/28/25 8:00:15 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Akero Therapeutics Inc.

      S-8 - Akero Therapeutics, Inc. (0001744659) (Filer)

      2/28/25 4:05:47 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Akero Therapeutics Inc.

      8-K - Akero Therapeutics, Inc. (0001744659) (Filer)

      2/28/25 8:30:54 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Akero Therapeutics Inc.

      10-K - Akero Therapeutics, Inc. (0001744659) (Filer)

      2/28/25 7:30:31 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Akero Therapeutics Inc.

      SCHEDULE 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

      2/14/25 12:58:08 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Akero Therapeutics Inc.

      SCHEDULE 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

      2/14/25 9:00:07 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Akero Therapeutics Inc.

      8-K - Akero Therapeutics, Inc. (0001744659) (Filer)

      1/30/25 7:52:31 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Akero Therapeutics Inc.

      424B5 - Akero Therapeutics, Inc. (0001744659) (Filer)

      1/29/25 5:08:49 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form FWP filed by Akero Therapeutics Inc.

      FWP - Akero Therapeutics, Inc. (0001744659) (Subject)

      1/27/25 9:35:27 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Akero Therapeutics Inc.

      424B5 - Akero Therapeutics, Inc. (0001744659) (Filer)

      1/27/25 4:53:08 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Akero Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Akero Therapeutics upgraded by BofA Securities with a new price target

      BofA Securities upgraded Akero Therapeutics from Neutral to Buy and set a new price target of $63.00 from $35.00 previously

      1/30/25 7:09:02 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on Akero Therapeutics with a new price target

      H.C. Wainwright reiterated coverage of Akero Therapeutics with a rating of Buy and set a new price target of $72.00 from $50.00 previously

      1/27/25 11:47:01 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup initiated coverage on Akero Therapeutics with a new price target

      Citigroup initiated coverage of Akero Therapeutics with a rating of Buy and set a new price target of $65.00

      11/18/24 7:26:08 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities resumed coverage on Akero Therapeutics with a new price target

      BofA Securities resumed coverage of Akero Therapeutics with a rating of Neutral and set a new price target of $30.00

      4/22/24 7:22:12 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Akero Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Akero Therapeutics with a rating of Overweight and set a new price target of $69.00

      9/19/23 7:07:52 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Akero Therapeutics with a new price target

      UBS initiated coverage of Akero Therapeutics with a rating of Buy and set a new price target of $83.00

      8/28/23 8:32:02 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Akero Therapeutics from Equal-Weight to Overweight and set a new price target of $65.00 from $40.00 previously

      1/27/23 7:07:18 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics upgraded by Evercore ISI with a new price target

      Evercore ISI upgraded Akero Therapeutics from In-line to Outperform and set a new price target of $50.00 from $10.00 previously

      9/14/22 7:10:26 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley reiterated coverage on Akero Therapeutics with a new price target

      Morgan Stanley reiterated coverage of Akero Therapeutics with a rating of Equal-Weight and set a new price target of $29.00 from $27.00 previously

      11/15/21 8:29:14 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Akero Therapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of Akero Therapeutics with a rating of Buy and set a new price target of $62.00 from $64.00 previously

      11/15/21 6:45:55 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Akero Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

      Among patients with baseline and week 96 biopsies, 39% of the 50mg EFX group (p=0.009) demonstrated ≥1 stage improvement in fibrosis with no worsening of MASH, representing a 24% effect size over placebo at 15% By ITT analysis, with all missing week 96 biopsies treated as failures, 29% of the 50mg EFX group (p=0.031) demonstrated ≥1 stage improvement in fibrosis with no worsening of MASH, representing a 17% effect size over placebo at 12% Investor webcast at 8:00 am ET Monday, January 27, 2025 SOUTH SAN FRANCISCO, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious me

      1/27/25 6:30:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

      Investor webcast on Monday, January 27, 2025, at 8:00 a.m. ET to present clinical data SOUTH SAN FRANCISCO, Calif., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, will hold an investor conference on Monday, January 27, 2025, at 8:00 a.m. ET to share preliminary topline week 96 results from its SYMMETRY study, a double-blind, placebo-controlled Phase 2b study evaluating the efficacy of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to metabolic dysfunction-associated steatohepatitis (MASH). Conferenc

      1/24/25 4:05:00 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

            50mg (75%, p<0.001) and 28mg (46%, p=0.07) EFX groups demonstrated ≥1 stage improvement in fibrosis without worsening of MASH, approximately three- and two-fold the placebo rate (24%) 50mg (36%, p<0.01) and 28mg (31%, p<0.01) EFX groups demonstrated ≥2 stage improvement in fibrosis without worsening of MASH, more than 10-fold the placebo rate (3%) EFX-treated patients experienced statistically significant improvements on nearly all histological endpoints by ITT analysis as well as the primary analysis of patients with week 96 biopsies Investor webcast at 8:00 am ET Monday, March 4, 2024 SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) --  Akero Therapeutics,

      3/4/24 6:00:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH

      SOUTH SAN FRANCISCO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease, will hold an investor conference on Monday, March 4 at 8:00 a.m. ET to share results after 96 weeks of treatment for its HARMONY study, a double-blind, placebo-controlled Phase 2b study evaluating the efficacy of efruxifermin (EFX) in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), fibrosis stage 2 or 3 (F2-F3). Conference Call / Webcast DetailsThe company will host a conference call and webcast with slide presentation at 8:00 a.m. ET on Monday

      2/29/24 8:00:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins

      22% (28mg EFX) and 24% (50mg EFX) of patients experienced at least a one-stage improvement in liver fibrosis with no worsening of NASH by week 36, compared to 14% for placebo 4% of patients in each EFX dose group experienced a three- or two-stage reversal of fibrosis with no worsening of NASH, compared to 0% for placebo 63% (28mg EFX) and 60% (50mg EFX) of patients experienced NASH resolution, representing statistically significant differences compared to 26% for placebo Investor webcast at 8:00 a.m. ET to further discuss data SOUTH SAN FRANCISCO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments

      10/10/23 7:00:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH

      SOUTH SAN FRANCISCO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, will hold an investor conference on Tuesday, October 10 at 8:00 a.m. ET to share topline week 36 results from its SYMMETRY study, a double-blind, placebo-controlled Phase 2b study evaluating the efficacy of efruxifermin (EFX) in patients with compensated cirrhosis due to non-alcoholic steatohepatitis (NASH). The topline results will include histology and changes from baseline in non-invasive measures of fibrosis, glycemic control, and lipoproteins

      10/9/23 4:05:00 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics' Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease

      Patients treated with EFX for 12 weeks combined with GLP-1 achieved a 65% relative reduction in liver fat, compared to a 10% relative reduction for GLP-1 alone 88% of patients treated with EFX combined with GLP-1 had normalized liver fat at week 12, compared with 10% of those treated with GLP-1 alone EFX-treated patients also experienced statistically significant improvements in liver enzymes and noninvasive markers of fibrosis, glycemic control, and lipids Investor webcast at 8:00 am ET today to further discuss data SOUTH SAN FRANCISCO, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatme

      6/5/23 7:00:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1

      SOUTH SAN FRANCISCO, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, will hold an investor conference on Monday, June 5 at 8:00 a.m. ET to share results from Cohort D of the Phase 2b SYMMETRY study. The primary aim of the 12-week study was to assess the safety and tolerability of efruxifermin (EFX) compared to placebo when added to an existing GLP-1 receptor agonist in patients with Type 2 diabetes and F1-F3 liver fibrosis due to NASH. In addition to results for the primary endpoint, the company will present data fo

      6/1/23 4:05:00 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • In Akero Therapeutics' Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks

      50mg (41%) and 28mg (39%) groups demonstrated ≥1 stage improvement in fibrosis without worsening of NASH, double the placebo rate (20%) 50mg (76%) and 28mg (47%) groups demonstrated NASH resolution without worsening of fibrosis, three to five times the placebo rate (15%) 50mg (41%) and 28mg (29%) groups demonstrated fibrosis improvement AND resolution of NASH, six to eight times the placebo rate (5%) EFX-treated patients also experienced statistically significant improvements in liver fat, liver enzymes, noninvasive fibrosis markers, glycemic control, lipoproteins, and body weight Investor webcast at 8:00 am ET today to further discuss data SOUTH SAN FRANCISCO, Calif., Sept. 13, 2022

      9/13/22 6:00:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics to Present Results from Phase 2b HARMONY Trial Investigating Efruxifermin in Patients with Pre-Cirrhotic NASH

      SOUTH SAN FRANCISCO, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, will hold an investor conference on Tuesday, September 13 at 8:00 a.m. ET to share results from its HARMONY study, a double-blind, placebo-controlled Phase 2b study evaluating the efficacy of efruxifermin (EFX) in patients with pre-cirrhotic non-alcoholic steatohepatitis (NASH), fibrosis stage 2 or 3 (F2-F3). Conference Call / Webcast DetailsThe company will host a conference call and webcast with slide presentation at 8:00 a.m. ET on Tuesday, Se

      9/8/22 4:01:00 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care